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1.

INTRODUCTION

The Declaration of Helsinki, which expresses an international consensus
on the ethical conduct of human subject research, declares that "[m]edical
progress is based on research that ultimately must include studies involving
human subjects."' Yet the pursuit of this progress has, unfortunately, been
one marked by repeated instances in which individuals have suffered
unreasonable and often unconsented to harm in pursuit of knowledge
intended to serve the greater good.
The history of medical research is one of repeated instances in which
individual subjects have suffered harm in the pursuit of acquiring
knowledge that is purportedly intended to increase the public's welfare.
Looking just to the recent history of human subject research in the United
States over the past fifteen years, we see repeated examples of good
intentions leading to unimaginable, and irreparable, harm.2 Although it is
difficult to know how many people die every year as a direct result of their
participation in research trials, the number may well run into the
thousands. To suggest that there needs to be further oversight of human
. Alvin R. Allison Professor of Law, Texas Tech University School of Law. Prof. Bard is
Associate Dean for Faculty Research and Development and directs the J.D./M.D. and Health
Law Programs. She also is an adjunct professor in the Department of Psychiatry at the
Texas Tech University School of Medicine. Thank you to Victoria Sutton, Ph.D. The
research on which this publication was based was made in part possible by Grant Number
U54 A1057156 from NIAID/NIH of which she is the Principal Investigator.
1. World Medical Association, WMA Declaration of Helsinki - Ethical Principles for
Medical Research Involving Human Subjects, http://www.wma.net/en/30publications/10
policies/b3/.
2. See Robin Fretwell Wilson, The Death of Jesse Gelsinger: New Evidence of the
Influence of Money and Prestige in Human Research, 36 AM. J. L. & MED. 295 (2010);
Diane Hoffman & Karen H. Rothenberg, Whose Duty is it Anyway?: The Kennedy Krieger
Opinion and its Implicationsfor Public Health Research, 6 J. HEALTH CARE L & POL'Y 109
(2002); Barbara A. Noah, Bioethical Malpractice: Risk and Responsibility in Human
Research, 7 J. HEALTH CARE L & POL'Y 175 (2004).

3.

See Noah, supra note 2, at 176 ("Although calculating the number of research-related
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subject research is not to criticize the personal ethics of the scientists doing
that research. There seems to be an inevitable, and in some ways
inexplicable, process in which research, which seems reasonable while it is
being done, is later exposed as unacceptably risky.4
Faced with the reality of both its inherent dangers and the seeming
impossibility of accurately appreciating the extent of these dangers as they
are occurring, the United States enacted the Medical Research Act of 1974,
which is now often referred to as "The Common Rule" because it has been
adopted by most federal agencies. Although a dramatic achievement in
protecting subjects, the Common Rule is at once excruciatingly complex for
those entities that are bound by it and provides no oversight for human
subjects of research neither funded by the federal government or part of a
clinical trial to sell a product requiring the approval of the Food and Drug
Administration ("FDA").5 Proposed rules announced by the Department of
Health and Human Services ("HHS") on July 22, 2011, address some of
these concerns, but fail to close the gap caused by the lack of U.S. oversight
for human subject research conducted outside the borders of the United
States. Indeed, it is quite possible that the new regulations will increase the
amount of research conducted overseas as costs for studies involving
human subjects rise.
II.

A.

CURRENT REGULATION

In the United States

Currently, unless it directly funds or oversees it, the U.S. law does not
directly regulate human subject research conducted overseas because the
controlling legal scheme only covers human subject research funded or
regulated by the federal government.
This research falls under the
jurisdiction of 45 C.F.R. 46, which is often referred to as "The Common
Rule"6 for the protection of human subjects because it has been widely
adopted by the many different federal agencies that conduct human subject
deaths and injuries has proven difficult, one expert suggests that as many as 5,000 people die
annually in federally-funded research protocols, while tens of thousands more suffer injuries.
Injuries in privately-funded research remain even more difficult to estimate due to the lack of
any unified tracking system."); Adil E. Shamoo, Adverse Events Reporting- The Tip of an
Iceberg, 8 ACCOUNTABILITY IN RES.197 (2001).
4. See generally JONATHAN D. MORENO, UNDUE RISK: SECRET STATE EXPERIMENTS ON
HUMANS (2000) (discussing a history of human subject research including the radiation
studies of the 1950's, the Army's LSD studies of the 1960's and the study of the natural
history of syphilis conducted by the U.S. Public Health Service through Tuskegee University
which was conducted in the United States which later was identified as unethical).
5. National Research Service Award Act of 1974, Pub. L. No. 93-348, 88 Stat. 342
(1974).
6. 45 C.F.R. § 46.101-124 (2009).
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research. While federal funding for research comes from many different
agencies, the primary source for medical research comes from funds
Congress allocates and awards through competitive grants offered by the
National Institutes of Health ("NIH"). In fiscal year 2010 the NIH oversaw
a budget of thirty-one billion dollars, which was for the most part
distributed to research universities.
In contrast, participants in privately funded research occurring within the
United States are protected only by existing common or statutory laws that
govern everyday behavior. For research harm resulting from a research
study, this means claims can be brought based on torts, contracts or even
criminal law. Almost all states have some laws directly applicable to
human subject research, but they are scattered across a number of different
categories such as privacy, including access to genetic information, and
often do not make distinctions between treatment and research.8 Some
states have adopted, in whole or in part, the Common Rule as controlling
law for research occurring within their jurisdiction,9 but only Maryland and
Virginia extend the Common Rule to all human subject research conducted
in their states regardless of funding source or type of study.'o California"
and New Yorkl 2 have enacted laws, which provide broad protections for
human subjects, but do not go so far as to adopt the Common Rule.
In an effort to close the gap between regulated and unregulated research,
the newly proposed regulations extend the Common Rule to all research
conducted at institutions which receive any federal research support.
The newly proposed regulations by HHS seek to do two perhaps
inherently contradictory things: "to simultaneously enhan[ce] protections
for research subjects and improve[e] the effectiveness of the federal
oversight system."' 3 In so doing, the regulations close at least one major gap
7. Testimony of Francis S. Collins, M.D., Ph.D., Director, National Institutes of Health
Supporting FY 2010 Budget Request (Apr. 28, 2010), http://www.nih.gov/about/director
/budgetrequest/fy201 Itestimony.pdf. See also Paul Basken, NIH Will Give Less and Demand
More in 2010, New Leader Says, CHRON. HIGHER ED., Jan.

17, 2010, available at

http://chronicle.com/article/NIH-Will-Give-LessDemand/63537/; NIH Research Portfolio
On-line Reporting Tools (June 24, 2011), http://report.nih.gov/reportmap.aspx (includes a
discussion of the specific amount NIH provides each university).
8. See NAT'L. CANCER INST. CANCER DIAGNOSIS PROGRAM, 50-STATE SURVEY OF LAWS
REGULATING THE COLLECTION, STORAGE, AND USE OF HUMAN TISSUE SPECIMENS AND
ASSOCIATED DATA FOR RESEARCH (2004), available at http://cancerdiagnosis.nci.nih.gov

/pdf/50StateSurvey.pdf.
9. See Edward P. Richards III, Louisiana State University, Medical Research and
Human Experimentation Law, http://biotech.law.lsu.edu/research/.
10. See Id.
11. See Univ. California-Irvine, Ethical Guidelines, Federal Regulations, and State
Statutes (Aug. 16, 2011), http://research.uci.edu/ora/hrpp/ethicaIguidelines.htm#state.

§§

12.

N.Y. PUB. HEALTH LAW

13.

Ezekiel J. Emanuel & Jerry Menikoff, Reforming the Regulations Governing
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by extending the Common Rule to all research sponsored by a university
that received any federal funding regardless of whether the specific project
is itself directly funded by the government.
In so regulating, HHS exercises the power granted the federal
government by the Supreme Court in Rumsfeld v. Forumfor Academic and
InstitutionalRights to require universities to comply with federal directives
if they receive not just direct federal funding for research, but also if they
enroll students who receive federal financial aid.14 Since this essentially
incorporates all but a handful of institutions of higher education, it provided
the federal government with very broad authority to regulate activities on
college and university campuses.' 5
Bringing all research done at
universities under the Common Rule is a substantial achievement, but it still
leaves major areas unregulated and in some ways could make things worse.
This is because the newly proposed regulations leave untouched human
subject research conducted by private companies that do not intend to use
their results in a way currently regulated by the federal government. As the
laws are currently written, those who serve as subjects in overseas drug
tests are not protected by the same laws that in the United States would
ensure their voluntary consent and on-ongoing safety. Although the FDA
stands in the position of goal keeper between the U.S. public and those who
wish to sell a drug, the agency lacks not only the resources, but the legal
authority to oversee the safety of every individual who takes part in the tests
and clinical trials, on which applications for approval of a new drug are
made. 16
B.

Internationally

We do not know how much human subject research is conducted
overseas by U.S.-based companies or by companies that market drugs
within the United States; however, there is no question that these studies are
taking place in large numbers. 17 According to Dr. Seth Glickman, a vocal
critic of this practice, "there are powerful forces luring clinical trials
overseas, including the lower cost of doing business and access to larger
Research with Human Subjects, NEw ENG. J.MED., July, 25, 2011, at 1.
14. Rumsfeld v. Forum for Academic & Institutional Rights, Inc., 547 U.S. 47, 59
(2006) (holding that private universities must allow military recruiters on campus or risk
eligibility for all federal funding).
15. See Loet Leydesdorff & Henry Etzkowitz, The Transformation of UniversityIndustry-Government Relations, ELECTRONIC J. Soc., Oct. 2001, available at
http://www.sociology.org/content/vol005.004/th.html (last visited Aug. 20, 2011).
16. The word "drugs" is used here to encompass FDA oversight of drugs, devices,
vaccines and biological.
17. See Yevgenia Shtilman, PharmaceuticalDrug Testing in the Former Soviet Union:
Contract Research Organizations as Broker-Dealers in an Emerging Testing Ground for
America's Big Pharma,29 B.C. THIRD WORLD L.J. 425 (2009).
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study populations.""
Glickman and others estimate that the large
pharmaceutical companies conduct between fifty and seventy percent of the
initial phases of research, Phase One and Two clinical trials, outside the
United States'9 - the practice continues because it is lucrative. As one
commentator notes, "[t]oday, the greatest obstacle to ensuring the health
and safety of participants in overseas trials may be the lack of regulation
over the [independent contractors] employed by Western pharmaceutical
manufacturers. Developing, unstable countries are generally ill-equipped to
oversee, much less manage, the clinical trials being held within their
borders."2 0
While there have been some efforts both in the United States and by
other countries at bringing the practice of overseas drug testing under some
sort of review, they are weakly written and weakly enforced. U.S. laws that
require the registering of clinical trials in order for them to form the basis of
an application for a drug, device, or biological for sale in the United States
are intended to prevent the hiding of bad results, not to protect clinical
subjects.2 1 When it comes to protecting subjects, the FDA is clear that it
does not demand compliance with U.S. law. The FDA advises applicants
that "if the drug is manufactured outside of the U.S. or its territories, the
trial sites are all outside of the U.S., and the trial is not being conducted
under an [investigational new drug application], then it would not be
considered to be subject to section 505 of the [Food, Drug, and Cosmetic]
Act or section 351 of the [Public Health Service] Act, and the clinical
investigation would not be an 'applicable drug clinical trial."' 22
Registry laws are even less able to protect subjects. Research that takes
the form of a pilot study, which is never intended for submission to U.S.
18. Overseas Drug Trials Test the System's Safety, Question Drugs' Efficacy (Feb. 18,
2009), http://unchealthcare.wordpress.com/2009/02/18/overseas-drug-trials-test-the-systemssafety-efficacy/.
19. Seth Glickman et al., Ethical and Scientific Implications of the Globalizations of
ClinicalResearch, N. ENGL. J. MED., Feb. 19, 2009, at 816 (estimating that "as of November
2007, approximately one-third of industry-sponsored Phase 3 clinical trials were conducted
solely outside the United States, and a majority of study sites (13,521 of 24,206) were
located outside the United States").
20. Shtilman, supra note 17, at 436. See also FDB Media, Clinical Research
Organization Services by Promedica International, http://www.fdbnetwork.com/ClinicalResearch-Org-CRO; Biores, Biomedical Research Directory, http://www.biores.org/dir/
Companies/ContractResearchOrganizations/.
21. World Health Org., About the WHO ICTRP, http://www.who.int/ictrp/about/en/; See
generally Carolyne R. Hathaway et al., "The Web of Clinical Trial Registration Obligations:
Have Foreign Clinical Trials Been Caught?," 64 FOOD & DRUG L.J. 261 (2009) (concluding
that companies need to comply with many different U.S. and international regulations when
conducting a clinical trial overseas).
22. Nat'l. Inst. of Health, Elaboration of Definitions of Responsible Party and
Applicable Clinical Trial 8 (Mar. 9, 2009), http://prsinfo.clinicaltrials.gov/Elaborations
OnDefinitions.pdf.
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regulators, is completely excluded from even these registries. Moreover,
the FDA does not require registration of every drug trial. One FDA
publication regarding clinical trials for serious and life-threatening diseases
notes that HHS, through the NIH, is required by the 1997 FDA
Modernization Act to establish "a registry of clinical trials [for both]
federally and privately funded trials of experimental treatments for serious
or life-threatening diseases."2 3
Many countries with their own active human subject research programs
have adopted some laws regulating human subject research that track the
principles in the doctrines of Helsinki.2 4 But even countries that have laws
covering harm caused by researchers have difficulty enforcing them. One
frequently cited code is the European Union's guidelines for "Good Clinical
Practice" by the International Conference on Harmonization.25 As Shtilman
writes, "[b]ecause there is no positive international law mandating CRO
compliance with the relevant domestic laws of the clinical studies'
sponsors, the resulting 'regulatory vacuum' makes it difficult for these
countries to ensure the welfare of trial participants and forces them to rely
on foreign data and foreign review processes."2 6
There are many other sources of guidelines but all, as their name
suggests, are voluntary.27 International organizations such as the European
International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use and the Council for
International Organizations of Medical Sciences working with the World
Health Organization all have codes of ethical conduct 28 and have made
attempts to track clinical trials, but their provisions are not enforceable
23. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, §
113(a)(2). The bare provisions of this statute are still being discussed and interpreted. See
Congressional Research Service, Clinical Trials Reporting and Publication (July 12, 2007),
available at http://www.fas.org/sgp/crs/misc/RL32832.pdf; Office of Legislative Pol'y &
Analysis, Access to Clinical Trial Information, http://olpa.od.nih.gov/legislation/109
/pendinglegislation/fact.asp; HHS et al., Guidance for Industry Information Program on
Clinical Trials for Serious or Life-Threatening Diseases and Conditions (Mar. 2002),
http://www.fda.gov/downloads/regulatoryinformation/
guidances/ucml26838.pdf. See also §§ 112-13, 117, 111 Stat. 2296, 2309-12, 2315-16
(1997) (codified at 21 U.S.C. § 356 (2000), 42 U.S.C. § 282 (2000), 21 U.S.C. § 355(i)
(2000))
24. New York Univ., Tutorial Chapter 16: What are researchers' obligations when doing
research in foreign countries?, http://www.nyu.edu/ucaihs/tutorial/16/.
25. See International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, Efficacy Guidelines, http://www.ich.org
/products/guidelines/efficacy/article/efficacyguidelines.html.
26. Shtilman, supra note 17, at 436.
27. See Office for Human Research Protections, International, http://www.hhs.gov
/ohrp/international/index.html.
28. See World Health Organization, Ethical Standards and Procedures for Research with
Human Beings, http://www.who.int/ethics/research/en/.

http://lawecommons.luc.edu/annals/vol21/iss1/19

6

Bard: Closing the Gaps in Human Subject Research Law: Regulating Clinic

2012]

Closing the Gaps in Human Subject Research Law

207

under U.S. law. There is, therefore, a significant legal gap because the FDA
does not require a sponsor presenting such an application to prove that their
clinical trials were conducted under the same regulations as if they had
occurred in the United States. Instead, the company must file Good
Clinical Practice, raising concerns about the extent to which the human
subjects were provided with informed consent and had adequate protection
against injury.
Congress already authorizes the FDA to oversee drug manufacturing
plants overseas, but the FDA does not interpret this as an extension to direct
oversight of clinical trials.29 What is needed to close the gaps is new
legislation that covers research activity within the United States, but also
which makes it illegal for U.S. companies to engage in risky human subject
research activities outside of the United States. There is no inherent reason
why the United States cannot enforce its laws outside of its territorial
boundaries.3 0 In a report discussing the application of criminal law outside
the United States, the Congressional Research Service concluded that "[t]he
Constitution does not forbid either Congressional or state enactment of laws
which apply outside the United States. Nor does it prohibit either the
federal government or the states from" applying American law in situation
where behavior outside the United States has an effect on events inside the
United States.3 ' There are many precedents for the extension of U.S. law,
including laws that prohibit bribery of foreign officials,3 2 tax evasion,
trademark abuse,33 travel for the purpose of engaging in sex with minors,

29. See E. M. Ambler, Plugging the GATTS and WTOs: Toward a Globalized
PharmaceuticalRegulatory Framework, 29 BIOTECHNOLOGY L. REP. 3 (2010) (arguing that
the FDA has the authority to negotiate international agreements and to inspect overseas drug
manufacturing plants but has not done so effectively because of lack of enforcement
resources and citing 21 U.S.C.A. § 381 which empowers the Secretary of Health and Human
Services and, by extension, the FDA to enforce the same regulatory standards on
prescription drug imports as on domestically produced prescription drugs); See also FDA
Division of Field Investigations, Guide to International Inspections and Travel, § 302.1 (Apr.
30, 2009), http://www.fda.gov/ICECI/Inspections/Foreignlnspections/default.htm ("The
intent of the international inspection program is to ensure that products manufactured in
foreign countries meet the same standards of quality, purity, potency, safety, and efficacy as
required of domestic manufacturers.").
30. See Developments in the Law- Extraterritoriality,124 HARv. L. REv., 1226, 1228
(2011) ("[A]state's extraterritorial application of its law can serve a range of state and nonstate interests, and also suggest that extraterritoriality may support the core values of the
international order as often as it harms them.").
31. Charles Doyle, Extraterritorial Application of American Criminal Law, Cong.
Research Serv. No. 94-166 A (Aug. 11, 2006), availableat http://www.au.af.mil/aulawc/
awcgate/crs/94-166.pdf (last visited Aug. 20, 2011).
32. Foreign Corrupt Practices Act of 1977, 15 U.S.C. §§ 78dd-1 to -3 (2006).
33. Trademark Act of 1946, Pub. L. No. 79-489, 60 Stat. 427 (codified as amended at 15
U.S.C. §§ 1051-127 (1988)).
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Indeed, the Justice
and deliberate invasion of child labor laws.34
Department recently announced its intent to investigate violations of the
Foreign Corrupt Practices Act in relation to the testing of medical devices
overseas. This is based on "[a] recent report by the HHS Office of
Inspector General [which] noted that eight percent of marketing
applications to the FDA in 2008 relied exclusively on foreign data, 80
percent of approved marketing applications for drugs and biologics relied
on at least one foreign clinical study, and 78 percent of all human subjects
were enrolled at foreign sites."3 5
Current efforts at seeking redress for subjects of medical research injured
overseas by American corporations are inadequate to address the scope of
the problem. For example, although some Nigerians whose children were
injured in drug trials conducted in their country by Pfizer were allowed to
sue on the Alien Tort Claims Act, 36 this is far from comprehensive
protection.
III.

CONCLUSION

Unfortunately, human subject research is a field where ethics has always
outpaced law. Often concerns about practices are realized and discussed
long before legislation is passed to address them. This is especially true in
the very profitable business of testing drugs for sale in the U.S. market.
The regulations proposed by HHS show great promise in closing one of
the serious gaps in oversight by requiring that all research conducted under
the auspices of a university or college that receives federal funding comply
with the Common Rule. However, since this rule does not extend any
regulatory oversight to research by an entity that does not receive federal
funding it fails to cover the increasingly large amount of research conducted
overseas. Indeed, increasing the regulation of research within the United
States may have the perverse effect of making overseas research more
attractive. It is well within the authority of the U.S. Congress to extend
34. See generally Mark Gibney, The ExtraterritorialApplication of U.S. Law: The
Perversion of Democratic Governance, the Reversal of Institutional Roles, and the
Imperative ofEstablishingNormative Principles,19 B.C. INT'L & COMP. L. REv. 297 (1996)
(tracing development of current doctrine that Congress has the authority to pass laws which
require compliance with U.S. law outside the borders of the United States if there is an effect
on events inside the United States).
35. Ed Silverman, Feds Probe Payments in Overseas Drug Trials (Aug. 9, 2010),
http://www.pharmalot.com/2010/08/feds-probe-payments-in-overseas-drug-trials/.
36. Pfizer, Inc. v. Abdullahi, 130 S.Ct. 3541 (June 29, 2010) (denying certiorari); Joe
Stephens, Pfizer to Pay $75 Million to Settle Trovan-Testing Suit, WASH. PosT, July 31,
2009 at Al5 (explaining that Pfizer has subsequently settled both lawsuits for a reported $75
million). See also Business & Human Rights Resources Centre, Case profile: Pfizer Lawsuit
(re Nigeria), http://www.business-humanrights.org/Categories/Lawlawsuits/Lawsuits
regulatoryaction/LawsuitsSelectedcases/PfizerlawsuitreNigeria.
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extraterritorial enforcement of the Common Rule to clinical research done
by companies that also do business in the United States. Just as it is illegal
to use child labor to make U.S. products in Asia or to bribe officials
overseas, it should be illegal to conduct medical research with human
subjects who do not have available to them the same protections ensured by
basic principles of human dignity.
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